Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESPRED: Desloratadine and Prednisolone in Allergic Rhinitis
NCT05214911Phase 3Completed
- Sponsor
- Eurofarma
- Start
- Jul 2024
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desloratadine and prednisolone in allergic rhinitis (AR) (2 arms), sponsored by Eurofarma. Primary endpoint: Total Nasal Symptom Score at 5 days. Started Jul 2024; status: completed.
02
Drugs
desloratadineprednisolone
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05214911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214911.